KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

(2014) Volker Heinemann et al.   LANCET ONCOLOGY

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study

(2013) B. Schultheis et al.   ANNALS OF ONCOLOGY

Regorafenib (BAY 73-4506): Antitumor and antimetastatic activities in preclinical models of colorectal cancer

(2013) Roberta Schmieder et al.   INTERNATIONAL JOURNAL OF CANCER

KRAS allel-specific activity of sunitinib in an isogenic disease model of colorectal cancer

(2013) D. P. Modest et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

(2012) D Strumberg et al.   BRITISH JOURNAL OF CANCER

A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

(2012) K. Mross et al.   CLINICAL CANCER RESEARCH

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines

(2012) Isabelle Messner et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Activation of the RAS/RAF/ERK Signaling Pathway Contributes to Resistance to Sunitinib in Thyroid Carcinoma Cell Lines

(2012) Annamaria Piscazzi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

(2012) Sabine Tejpar et al.   JOURNAL OF CLINICAL ONCOLOGY

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status

(2011) Dominik P. Modest et al.   ANTI-CANCER DRUGS

The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial

(2011) D.P. Modest et al.   INTERNATIONAL JOURNAL OF CANCER

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

AAV-mediated gene targeting methods for human cells

(2011) Iram F Khan et al.   Nature Protocols

Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity

(2010) Scott M. Wilhelm et al.   INTERNATIONAL JOURNAL OF CANCER

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

(2010) Wendy De Roock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study

(2010) Jean-Yves Douillard et al.   JOURNAL OF CLINICAL ONCOLOGY

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer

(2009) Jens Neumann et al.   PATHOLOGY RESEARCH AND PRACTICE

Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses

(2008) F. Di Nicolantonio et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA